GlassScriptPhysician profile
Falon Pollifrone
NPI 1376184655
$5,431.22
in general payments reported to CMS, 2019-2025
27 companies · $1,471 in 2025
The $1,471 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $282 · 2022: $985 · 2023: $1,412 · 2024: $1,281 · 2025: $1,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,164.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $700.14 | 2022-2025 | Caplyta |
| Abbvie INC. | $536.60 | 2022-2025 | |
| Alkermes, INC. | $462.93 | 2022-2025 | Aristada, Lybalvi |
| Corium, LLC | $404.23 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $381.70 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Almatica Pharma LLC | $378.31 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Lundbeck LLC | $317.96 | 2021-2025 | Rexulti, Brintellix |
| Ironshore Pharmaceuticals INC. | $281.58 | 2021-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $273.45 | 2021-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $253.31 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $240.52 | 2021-2025 | Ingrezza |
| Bausch Health US, LLC | $225.46 | 2021-2025 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $138.09 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $131.38 | 2023-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $123.40 | 2023-2025 | Uzedy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $91.71 | 2024-2025 | Auvelity, Sunosi |
| Validus Pharmaceuticals LLC | $77.96 | 2022-2023 | Equetro |
| Vanda Pharmaceuticals INC. | $68.87 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $66.56 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $59.90 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $57.19 | 2022-2023 | Spravato |
| Collegium Pharmaceutical, INC. | $41.52 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $37.02 | 2025 | Zurzuvae |
| Noven Therapeutics, LLC | $29.10 | 2024 | Xelstrym |
| Tempus Ai, INC | $21.32 | 2024 | |
| Vertical Pharmaceuticals, LLC | $17.58 | 2024 | Relexxii |
| Avanir Pharmaceuticals, INC. | $13.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Falon Pollifrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.